Compared to the single CD19 group, the tandem CD19/CD22 group had an increased CR rate in patients with the following characteristics: no history of allo-HSCT (84.5% vs. 100.0%, P = 0.004), no EMD (88.0% vs. 100.0%, P = 0.013), a high tumor burden (78.2% vs. 100.0%, P = 0.014), and no complex karyotype (83.0% vs. 97.8%, P = 0.011). This evidence concerns the gene CD22 and neoplasm.